IMWG consensus on risk stratification in multiple myeloma. - Wikidata - awgldk - TriplyDB

IMWG consensus on risk stratification in multiple myeloma.

IMWG consensus on risk stratification in multiple myeloma.

http://www.wikidata.org/entity/Q38131380

about

European perspective on multiple myeloma treatment strategies in 2014 Recent advances in multiple myeloma: a Korean perspective Towards Stratified Medicine in Plasma Cell Myeloma Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice Are maintenance and continuous therapies indicated for every patient with multiple myeloma?Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma.Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.MicroRNA: important player in the pathobiology of multiple myeloma Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma.Implications of heterogeneity in multiple myeloma.Multiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapy Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.Multiple Myeloma: Treatment is Getting Individualized Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.ESRD due to Multiple Myeloma in the United States, 2001-2010.SnapShot: Multiple Myeloma The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Target fluorescence in-situ hybridization (Target FISH) for plasma cell enrichment in myeloma.Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma.N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma.European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China.The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.The Evolution of Prognostic Factors in Multiple Myeloma.Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.The potential of miRNAs as biomarkers for multiple myeloma.Controversies in multiple myeloma: to transplant or not?Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations.Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.

P2860

Q27005966-4B0E7499-4E98-434C-8D50-5FCAC9978B0B Q28074521-139CCB12-5D24-42F1-8D1F-BF3975C9EBE0 Q28074994-7D74E422-279C-4868-B832-4C6B077F6D19 Q28077567-E4067698-EF73-4DDF-90FA-AD4D79AA2941 Q30249790-545B4FC3-B7F9-485B-9F39-16F30E2D1FEE Q31154933-CF46266E-41EC-4F4B-9761-9423D0A7E10E Q33439437-9CD28389-F469-4908-9922-79095C26008F Q33733709-9EBDFF34-D39B-4453-BDCF-AAA65D970B34 Q33785935-B5FB1F02-3697-4D9F-A6EC-5202B378F814 Q33786861-9C45C697-6EAD-4CE8-8DD6-B5AF1356DFA8 Q33786986-D78F67F9-DE2A-4293-9855-FAEEF9970582 Q33914824-B77BF727-113D-498C-AD83-500C034A3C3C Q35061518-73AD64AB-5789-46E3-BDD2-613442F6C9EC Q35220639-89521552-C95B-44B9-9F33-0EA09EFB15B3 Q35724013-9253581E-5097-4184-A4BC-88C31640A780 Q35789280-17B8507F-5F12-4ACB-90CB-27302360951A Q35832389-B0597A77-2F4F-4B3F-A6A4-99E5B7EF0C58 Q35944156-599F87D6-EC1C-4490-AEAE-0E3BF2F9A9F6 Q36169794-9633A109-22DB-436F-94A7-DC21CBF7A5C0 Q36193181-7B772EDE-B833-4EB2-B44C-5EA6B4734844 Q36522964-640F93E0-F148-4692-978A-1F46279BE298 Q36799760-6BC19F77-8B06-4ED0-8F75-C59D925E8FA6 Q36849170-D167111B-CD67-4CE1-983B-D669C64E2506 Q36894316-91F7754C-5702-43AA-BF79-84464BD00D2E Q36962747-A4F3AC50-5A97-471D-885F-EB973A05C4B5 Q36993367-8EE2C3C7-6018-4375-86E7-E99D35D18FD4 Q37037265-C4DB2E25-5411-4D25-9E1D-E191A93F0490 Q37178643-CF5F3BF6-3321-4C14-9CD3-C0CEFF7325A8 Q37429898-EA52F365-895F-4E41-B5EB-393E79F3A222 Q37456396-01683E2B-C70A-487C-9259-D0D1C6BE4C01 Q37552008-EC847B30-8B94-4C0E-9E67-9F824FC6457C Q37615538-3ABDB5A5-9042-4E42-9AA1-494AFC30A99B Q37644252-FC44124B-9CFD-4891-AA29-A1478F5F1F77 Q37683483-37618657-C7DF-4526-AFD6-7FDC06EF2407 Q37709342-B640D05D-C6AC-4C8D-8C54-0A3DB153A50B Q38237446-23287C45-697F-41EA-849F-3EA7B814BBA5 Q38242006-73FFBB0E-4CF3-4881-8F6E-316EA45AFD6F Q38316150-753FA779-24EE-45CD-9204-26A86294D7C4 Q38367654-BCB8B521-DB45-40FD-9995-0E202206375E Q38385465-657B98C0-5C0B-4827-AD46-A8835A9C205E

P2860

IMWG consensus on risk stratification in multiple myeloma.

http://www.wikidata.org/entity/Q38131380

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

IMWG consensus on risk stratification in multiple myeloma.

@en

type

label

IMWG consensus on risk stratification in multiple myeloma.

@en

prefLabel

IMWG consensus on risk stratification in multiple myeloma.

@en

P1433

Q38131380-932D630D-5049-4CD2-A57A-F35F559C6ED3

P1476

Q38131380-158142E8-EE42-4071-BDE6-D3721D235EED

P2093

Q38131380-412CA62B-93E9-4BC1-BCA2-DA3C5DD9444F

Q38131380-432F1E9B-52C7-411E-95A7-401F362B630C

Q38131380-43C6BEC5-D579-4876-A912-2D2E546F7927

Q38131380-453A544C-4AB1-4041-B6AF-F8280B143579

Q38131380-48BD4071-93E3-40CC-9240-C62608EBD933

Q38131380-7E7121E9-92FB-4838-BC2A-C4793E7223D7

Q38131380-A8F22BA5-9978-41CC-BCC4-22374815DB3A

Q38131380-AACCDD03-1D48-48C5-91F8-95565A34F417

Q38131380-C23190AB-BA84-4D71-B0FF-A05741F797B3

Q38131380-D3D3FBED-C311-4540-A0F4-CD188FA9CD97

P2860

Q38131380-049253CE-6B02-4DBA-BC86-F85E1808A62B

Q38131380-06CBD86F-155E-4EAF-9819-67AEA76EE63F

Q38131380-0B1C369E-FD43-4854-B379-B3EAF1EF90E3

Q38131380-0F760720-9F17-4A9F-B32D-59DEF025C6AF

Q38131380-131BDD94-6DAF-4C24-8D25-B0D3572EFD55

Q38131380-1C900720-97A3-4FE8-9902-E35D72987ACB

Q38131380-1EF7DEB5-787C-4253-8D3E-67B36C4C847B

Q38131380-1F93BD26-29AA-4315-BA3E-28746E4F0AF6

Q38131380-2C87E1F5-F6D7-40C9-B479-D17FE9D6DA36

Q38131380-3137ED45-C1B9-48BE-9988-7CCBF492F139

P2888

Q38131380-3C65BC6D-E520-408D-8B4C-2A6466E4C6AF

P304

Q38131380-4428E033-1414-450B-8838-363F8F9F9103

P31

Q38131380-2ADF9215-F0C8-449E-B00A-5017CA73E36E

P356

Q38131380-5B2ED294-24B5-48A4-A896-EC752612BFE2

P433

Q38131380-45EAC6F5-EF70-492F-8201-1037C90A09C7

P478

Q38131380-DB87BFEF-66CD-45BF-BA3E-BF65494A2161

P50

Q38131380-24D6DE7B-904A-4166-A054-FCA221A5C517

Q38131380-4A79A260-BE9D-44BD-988A-8EFAA9CE2B09

Q38131380-6F09E353-7EB2-4479-9DB8-23E2427CF792

P577

Q38131380-FDEF138C-84C5-483C-8BA9-B82E5EF5B854

P6179

Q38131380-DC5F0D49-89AD-449F-9DCF-4C485A5A4DBA

P698

Q38131380-5F12B987-EFBE-4CE1-B2F6-C743CEB87A76

P356

P1433

P1476

IMWG consensus on risk stratification in multiple myeloma.

@en

P2093

A Palumbo

http://www.w3.org/2001/XMLSchema#string

B G M Durie

http://www.w3.org/2001/XMLSchema#string

C-S Chim

http://www.w3.org/2001/XMLSchema#string

H Avet-Loiseau

http://www.w3.org/2001/XMLSchema#string

H Goldschmidt

http://www.w3.org/2001/XMLSchema#string

J S Miguel

http://www.w3.org/2001/XMLSchema#string

M Cavo

http://www.w3.org/2001/XMLSchema#string

N Munshi

http://www.w3.org/2001/XMLSchema#string

P Sonneveld

http://www.w3.org/2001/XMLSchema#string

S Lentzsch

http://www.w3.org/2001/XMLSchema#string

P2860

Initial genome sequencing and analysis of multiple myeloma

The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.

Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma.

P2888

P304

269-277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2013.247

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

International Myeloma Working Group

P577

2013-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1016945153

http://www.w3.org/2001/XMLSchema#string

P698

23974982

http://www.w3.org/2001/XMLSchema#string